BioSpace News Archive

M6P Therapeutics Presents M002 Gene Therapy Preclinical Proof-of-Concept Data for the Treatment of Mucolipidosis Type II at the ASGCT 24 th Annual Meeting - Preclinical data provide proof of concept for M002 to restore cellular uptake and lysosomal delivery and attenuate phenotype in mouse models of mucolipidosis type II -

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2021 (“Q1-F2021”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.

Biom Pharmaceuticals’ VagiBiom® feminine product is now available in all Walmart stores. This novel microbiome-focused formulation was presented at Walmart’s Made in USA Open Call competition in October 2020 and got selected for launch in all Walmart stores.

Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel.

Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Dr. Arnot joins an elite board assembled to aid the advancement of innovative technologies being developed to address brain injury and other life saving medical conditions

Positive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021

RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, reported financial results for the first quarter ended March 31, 2021.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research.